Current Assets
Available For Sale Securities Debt Securities Current
Royalty Pharma Available For Sale Securities Debt Securities Current increased by 16.5% to $21.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 81.0%, from $12.10M to $21.90M. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows a downward trend with a -23.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026
How to read this metric
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
Detailed definition
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Peer comparison
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
Metric ID:
current_assets_available_for_sale_securities_debt_securi_87ec82Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $68.70M | $67.02M | $66.00M | $64.80M | $363.70M | $409.35M | $1.30M | $2.50M | $5.10M | $5.30M | $18.30M | $29.00M | $38.50M | $48.50M | $58.20M | $12.10M | $13.20M | $16.10M | $18.80M | $21.90M |
| QoQ Change | — | -2.5% | -1.5% | -1.8% | +461.3% | +12.6% | -99.7% | +92.3% | +104.0% | +3.9% | +245.3% | +58.5% | +32.8% | +26.0% | +20.0% | -79.2% | +9.1% | +22.0% | +16.8% | +16.5% |
| YoY Change | — | — | — | — | +429.4% | +510.8% | -98.0% | -96.1% | -98.6% | -98.7% | >999% | >999% | +654.9% | +815.1% | +218.0% | -58.3% | -65.7% | -66.8% | -67.7% | +81.0% |
Range$1.30M – $409.35M
CAGR-21.4%
Avg YoY Growth+276.7%
Median YoY Growth+11.4%
Current Streak4 quarters growth
Available For Sale Securities Debt Securities Current at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's available for sale securities debt securities current?
- Royalty Pharma (RPRX) reported available for sale securities debt securities current of $21.90M in Q1 2026.
- How has Royalty Pharma's available for sale securities debt securities current changed year-over-year?
- Royalty Pharma's available for sale securities debt securities current increased by 81.0% year-over-year, from $12.10M to $21.90M.
- What is the long-term trend for Royalty Pharma's available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Royalty Pharma's available for sale securities debt securities current has grown at a -23.1% compound annual growth rate (CAGR), from $69.98M to $18.80M.
- What does available for sale securities debt securities current mean?
- Short-term investments in debt securities that the company intends to sell within a year.